Vascular Solutions Inc. (NASDAQ:VASC) hit a new 52-week high on Wednesday . The company traded as high as $47.40 and last traded at $47.34, with a volume of 74,928 shares changing hands. The stock had previously closed at $47.07.

A number of brokerages have recently weighed in on VASC. Piper Jaffray Cos. raised their price objective on shares of Vascular Solutions from $45.00 to $49.00 and gave the company an “overweight” rating in a report on Tuesday, July 26th. Canaccord Genuity restated a “buy” rating on shares of Vascular Solutions in a report on Wednesday. Zacks Investment Research lowered shares of Vascular Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th. TheStreet upgraded shares of Vascular Solutions from a “hold” rating to a “buy” rating in a report on Monday, July 25th. Finally, Sidoti downgraded shares of Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 target price on the stock. in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Vascular Solutions has a consensus rating of “Buy” and an average price target of $47.38.

The company has a market cap of $828.02 million and a PE ratio of 87.67. The company’s 50-day moving average price is $43.32 and its 200-day moving average price is $35.68.

Vascular Solutions (NASDAQ:VASC) last released its quarterly earnings data on Monday, July 25th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.03. During the same quarter in the prior year, the firm earned $0.29 earnings per share. The business had revenue of $41.20 million for the quarter, compared to analysts’ expectations of $41.40 million. Vascular Solutions’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts predict that Vascular Solutions Inc. will post $1.24 earnings per share for the current fiscal year.

In other Vascular Solutions news, CFO James Hennen sold 11,785 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $38.12, for a total transaction of $449,244.20. Following the completion of the sale, the chief financial officer now directly owns 45,073 shares in the company, valued at $1,718,182.76. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Howard Root sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $45.11, for a total transaction of $1,804,400.00. Following the sale, the chief executive officer now owns 347,840 shares of the company’s stock, valued at $15,691,062.40. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Vascular Solutions stock. Nationwide Fund Advisors raised its stake in Vascular Solutions Inc. (NASDAQ:VASC) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,649 shares of the medical device company’s stock after buying an additional 153 shares during the period. Nationwide Fund Advisors owned about 0.18% of Vascular Solutions worth $1,088,000 as of its most recent SEC filing.

Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.